45 related articles for article (PubMed ID: 25301453)
21. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
22. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
23. An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels.
Wang Z; Hu J; Qiu SJ; Huang XW; Dai Z; Tan CJ; Zhou J; Fan J
Expert Opin Investig Drugs; 2011 Aug; 20(8):1039-45. PubMed ID: 21671804
[TBL] [Abstract][Full Text] [Related]
24. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
Ischenko I; Guba M; Yezhelyev M; Papyan A; Schmid G; Green T; Fennell M; Jauch KW; Bruns CJ
Angiogenesis; 2007; 10(3):167-82. PubMed ID: 17486419
[TBL] [Abstract][Full Text] [Related]
25. The bisphosphonate incadronate inhibits intraperitoneal dissemination in an in vivo pancreatic cancer model.
Takiguchi S; Nishino Y; Inoue K; Ikeda M; Kataoka Y; Matsusue K; Nishiyama K; Iguchi H
Oncol Rep; 2012 Jul; 28(1):111-6. PubMed ID: 22484715
[TBL] [Abstract][Full Text] [Related]
26. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
27. A novel anticancer diarylurea derivative HL-40 as a multi-kinases inhibitor with good pharmacokinetics in Wistar rats.
Lu YY; Zhao CR; Wang RQ; Li WB; Qu XJ
Biomed Pharmacother; 2015 Feb; 69():255-9. PubMed ID: 25661367
[TBL] [Abstract][Full Text] [Related]
28. A novel activity from an old compound: Manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis.
Guzmán EA; Johnson JD; Linley PA; Gunasekera SE; Wright AE
Invest New Drugs; 2011 Oct; 29(5):777-85. PubMed ID: 20352293
[TBL] [Abstract][Full Text] [Related]
29. Neamine inhibits growth of pancreatic cancer cells in vitro and in vivo.
Liu YP; Wu YL; Zhang XY; Hu GF; Wu YX
J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):82-87. PubMed ID: 26838745
[TBL] [Abstract][Full Text] [Related]
30. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
[TBL] [Abstract][Full Text] [Related]
31. The effects and mechanisms of a biosynthetic ginsenoside 3β,12β-Di-O-Glc-PPD on non-small cell lung cancer.
Huang LL; Tang M; Du QQ; Liu CX; Yan C; Yang JL; Li Y
Onco Targets Ther; 2019; 12():7375-7385. PubMed ID: 31571900
[TBL] [Abstract][Full Text] [Related]
32. Silencing Aurora A leads to re-sensitization of breast cancer cells to Taxol through downregulation of SRC-mediated ERK and mTOR pathways.
Li Y; Zhou W; Tang K; Chen X; Feng Z; Chen J
Oncol Rep; 2017 Oct; 38(4):2011-2022. PubMed ID: 28849180
[TBL] [Abstract][Full Text] [Related]
33. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
34. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
Yun SM; Jung KH; Lee H; Son MK; Seo JH; Yan HH; Park BH; Hong S; Hong SS
Cancer Lett; 2013 May; 331(2):250-61. PubMed ID: 23340175
[TBL] [Abstract][Full Text] [Related]
35. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.
Tong WG; Ding XZ; Hennig R; Witt RC; Standop J; Pour PM; Adrian TE
Clin Cancer Res; 2002 Oct; 8(10):3232-42. PubMed ID: 12374694
[TBL] [Abstract][Full Text] [Related]
36. (-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC‑1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity.
Kim SO; Kim MR
Int J Oncol; 2013 Jan; 42(1):349-58. PubMed ID: 23135610
[TBL] [Abstract][Full Text] [Related]
37. The molecular mechanisms of a novel multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth.
Li Y; Tang K; Zhang L; Li C; Niu F; Zhou W; Yang H; Feng Z; Chen X
Cancer Lett; 2015 Jan; 356(2 Pt B):392-403. PubMed ID: 25301453
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
